What is Allermetrix?
AllerMetrix specializes in improving allergy outcomes through accurate diagnostics for peanut allergies. The company's core mission is to identify true peanut-positive patients, thereby removing uncertainty from allergy testing. This focus serves individuals affected by peanut allergies and healthcare providers who require dependable diagnostic solutions. AllerMetrix is committed to advancing allergy management and enhancing patient care through its specialized services.
How much funding has Allermetrix raised?
Allermetrix has raised a total of $72K across 1 funding round:
Debt
$72K
Debt (2021): $72K with participation from PPP
Key Investors in Allermetrix
PPP
Public-Private Partnership
What's next for Allermetrix?
With the recent influx of substantial expansion capital, Allermetrix is poised for significant scaling and further development of its diagnostic technologies. The company's strategic positioning at a Series B/C stage suggests a focus on expanding its market reach, potentially through new partnerships or broader adoption of its testing services. Future initiatives will likely concentrate on solidifying its leadership in peanut allergy diagnostics and exploring opportunities to address other allergy-related diagnostic needs, driving innovation in patient care and clinical decision-making.
See full Allermetrix company page
